Siren, L.L.C. Aadi Bioscience, Inc. Call Options Transaction History
Siren, L.L.C.
- $1.76 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AADI
# of Institutions
55Shares Held
32.4MCall Options Held
2.6KPut Options Held
2.1K-
Qvt Financial LP New York, NY4.52MShares$7.72 Million0.85% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.17MShares$7.12 Million0.23% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.7MShares$6.33 Million0.29% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA3.41MShares$5.83 Million11.51% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.85MShares$4.87 Million0.08% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $35.9M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...